Anderson Kenneth Carl 4

What Happened

• Kenneth C. Anderson, a non-employee director of C4 Therapeutics (ticker CCCC), was issued 4,259 shares as an award/acquisition on April 1, 2026. The filing lists a per-share value of $2.70 based on the April 1, 2026 closing price, for a total reported value of $11,499.
• This was an issuance under the company’s Non-Employee Director Compensation Policy; the reporting person elected to receive shares in lieu of cash compensation (routine director compensation rather than an open-market purchase).

Key Details

• Transaction date and price: April 1, 2026; 4,259 shares at $2.70 per share (total $11,499). Price based on closing market price (footnote).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Notable footnotes: F1 — shares issued under the director compensation policy elected in lieu of cash; F2 — price based on closing market price; F3–F7 — several blocks of shares are held in various Kenneth and Cynthia Anderson trusts, and the reporting person disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
• Filing timeliness: Form filed April 3, 2026 for an April 1 transaction; this appears to be within the standard two-business-day Form 4 reporting window.

Context

• Awards to non-employee directors are typically routine compensation; receiving shares in lieu of cash is a standard alternative payout method and should be viewed as compensation rather than a direct buying signal.